Emicizumab prophylaxis and health-related outcomes in persons with hemophilia a (PwHA) with inhibitors: HAVEN 1 study

被引：0
|
作者：
Oldenburg, J. [1 ]
Mahlangu, J. N. [2 ,3 ]
Bujan, W. [4 ]
Trask, P. C. [5 ]
von Mackensen, S. [6 ]
Callaghan, M. U. [7 ]
Young, G. [8 ]
Asikanius, E. [9 ]
Peyvandi, F. [10 ]
Santagostino, E. [10 ]
Kruse-Jarres, R. [11 ]
Negrier, C. [12 ]
Kessler, C. [13 ]
Levy, G. G. [14 ]
Windyga, J. [15 ]
Shima, M. [16 ]
机构：
[1] Univ Klinikum Bonn, Bonn, Germany
[2] Univ Witwatersrand, Fac Hlth Sci, Haemophilia Comprehens Care Ctr, Johannesburg, South Africa
[3] NHLS, Johannesburg, South Africa
[4] Inst Costarricense Invest Cient, San Jose, Costa Rica
[5] Genentech Inc, San Francisco, CA 94080 USA
[6] Univ Med Ctr Hambur Eppendorf, Dept Med Psychol, Hamburg, Germany
[7] Childrens Hosp Michigan, Detroit Med Ctr, Detroit, MI 48201 USA
[8] Univ Southern Calif, Keck Sch Med, Childrens Hosp Los Angeles, Los Angeles, CA USA
[9] F Hoffmann La Roche Ltd, Basel, Switzerland
[10] Osped Maggiore Policlin, IRCCS Ca Granda Fdn, Milan, Italy
[11] Univ Washington, Washington Ctr Bleeding Disorders BloodWorks NW, Seattle, WA 98195 USA
[12] Univ Claude Bernard, Louis Pradel Cardiol Hosp, Lyon, France
[13] Georgetown Univ, Med Ctr, Washington, DC 20007 USA
[14] Genentech Inc, Pharma Dev Oncol, San Francisco, CA 94080 USA
[15] Inst Hematol & Transfus Med, Warsaw, Poland
[16] Nara Med Univ, Dept Pediat, Kashihara, Nara, Japan
来源：
HAEMOPHILIA | 2018年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P120
引用
收藏
页码：89 / 90
页数：2
相关论文
共 50 条
  • [41] Exposure-Bleeding Count Modeling of Emicizumab for the Prophylaxis of Bleeding in Persons with Hemophilia A with/Without Inhibitors Against Factor VIII
    Jonsson, Fredrik
    Schmitt, Christophe
    Petry, Claire
    Mercier, Francois
    Frey, Nicolas
    Retout, Sylvie
    CLINICAL PHARMACOKINETICS, 2021, 60 (07) : 931 - 941
  • [42] Sustained Improvement in Health-Related Quality of Life in Patients with Hemophilia A with or without Inhibitors Treated with Fitusiran Prophylaxis
    Cano, Viridiana
    Bartelt-Hofer, Jose
    Hu, Wenruo
    Andersson, Shauna R.
    Dasmahapatra, Pronabesh
    Von Mackensen, Sylvia
    BLOOD, 2021, 138
  • [43] A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors
    Young, Guy
    Liesner, Ri
    Chang, Tiffany
    Sidonio, Robert, Jr.
    Oldenburg, Johannes
    Jimenez-Yuste, Victor
    Mahlangu, Johnny
    Kruse-Jarres, Rebecca
    Wang, Michael
    Uguen, Marianne
    Doral, Michelle Y.
    Wright, Lilyan Y.
    Schmitt, Christophe
    Levy, Gallia G.
    Shima, Midori
    Mancuso, Maria Elisa
    BLOOD, 2019, 134 (24) : 2127 - 2138
  • [44] A Phase IV, Multicenter, Open-Label Study of Emicizumab Prophylaxis in Persons with Hemophilia a with or without FVIII Inhibitors Undergoing Minor Surgical Procedures
    Escobar, Miguel A.
    Dunn, Amy
    Quon, Doris
    Trzaskoma, Ben
    Lee, Lucy
    Ko, Richard H.
    Carpenter, Shannon L.
    BLOOD, 2020, 136
  • [45] Bleeding events and safety outcomes in persons with hemophilia A (PWHA) without inhibitors: non-interventional study (NIS) from a real-world setting
    Kruse-Jarres, R.
    Oldenburg, J.
    Santagostino, E.
    Shima, M.
    Kempton, C.
    Kessler, C. M.
    Lehle, M.
    Chebon, S.
    Bienz, N. Selak
    Asikanius, E.
    Mahlangu, J.
    HAEMOPHILIA, 2018, 24 : 116 - 117
  • [46] REAL-WORLD DATA ON EMICIZUMAB PROPHYLAXIS IN OLDER PERSONS WITH HEMOPHILIA A: A RETROSPECTIVE SINGLE CENTER COHORT STUDY
    Vemuru, Shalini
    Fedewa, Stacey
    Kempton, Christine
    AMERICAN JOURNAL OF HEMATOLOGY, 2024, 100 : 129 - 129
  • [47] EMICIZUMAB PROPHYLAXIS IN PEOPLE WITH HAEMOPHILIA A (PWHA), AGED ≥50 YEARS, WITH COMORBIDITIES - POOLED DATA FROM FOUR PHASE 3 STUDIES (HAVEN 1, 3, 4, AND STASEY)
    Jimenez-Yuste, V.
    Oldenburg, J.
    Tzeng, E.
    Trzaskoma, B.
    Sanabria, F.
    Mahlangu, J.
    HAEMOPHILIA, 2022, 28 : 50 - 50
  • [48] Emicizumab Prophylaxis in Adolescent/Adult Patients with Hemophilia A Previously Receiving Episodic or Prophylactic Bypassing Agent Treatment: Updated Analyses from the HAVEN 1 Study
    Mancuso, Maria Elisa
    Callaghan, Michael U.
    Kruse-Jarres, Rebecca
    Kempton, Christine L.
    Xu, Jin
    Catalani, Olivier
    Asikanius, Elina
    Levy, Gallia G.
    Shima, Midori
    Young, Guy
    Oldenburg, Johannes
    BLOOD, 2017, 130
  • [49] Fitusiran Prophylaxis Improves Health-Related Quality of Life in People with Hemophilia a or B, with or without Inhibitors: Results of ATLAS-PPX Study
    Kenet, Gili
    Nolan, Beatrice
    Matsushita, Tadashi
    Young, Guy
    Quan, Ting
    Cano, Viridiana
    Sussebach, Christian
    Andersson, Shauna
    Mei, Baisong
    Afonso, Marion
    Kavakli, Kaan
    BLOOD, 2022, 140 : 7977 - 7978
  • [50] Health-related quality of life in hemophilia patients with inhibitors receiving prophylaxis with anti-inhibitor coagulant complex (AICC): results from AICC prophylaxis study
    Stasyshyn, O.
    Antunes, S.
    Mamanov, V
    Ye, X.
    Xiong, Y.
    Tangada, S.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2013, 11 : 719 - 719
12345